|
|
|
|
Friday September 27, 2019
TherapeuticsMD (TXMD)
On Track for Annovera Soft Launch
TherapeuticsMD (TXMD) is a specialty pharmaceutical company that focuses on the development and commercialization of women’s hormone replacement products that are formulated to reduce the symptoms and health risks caused by menopause. TX-004HR, is an applicator-free vaginal estradiol softgel capsule in development for the treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA), due to menopause, and TX-001HR, a bio-identical hormone combination of 17ß-estradiol and progesterone in a single, oral softgel, for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause and Annovera is a small, soft, flexible vaginal contraceptive ring. In addition to the clinical trials for hormone therapy, TXMD also manufactures and distributes branded and generic prescription prenatal vitamins, iron supplements.
Ahu Demir, Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Annovera soft launch begins next week. Annovera is a long-acting (up to a year) reversible birth control product. The soft launch is set to begin the week of September 30th. It currently has 40% unrestricted coverage by commercial health plans including no co-pay with Anthem (covering 7.3% lives) and Kaiser (covering 3.9% lives). The full-scale launch, potentially supported by additional payers’ coverage, is expected in Q1 2020.
- Imvexxy and Bijuva commercial uptake continues to grow. The company reported an increased number of patients (+12%, 87,400 patients) and prescribers (+7%, 14,800 prescribers), while a slight decline in paid scripts (-1%, 44,600) through August compared to July. Bijuva reached 6,800 patients and…
Get full report on Channelchek desktop.
This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.